Drugs /

liposomal daunorubicin

Back to Drugs List

Overview

Generic Name(s):
liposomal daunorubicin
Trade Name(s):
Daunoxome

Clinical Trials

View Clinical Trials for liposomal daunorubicin

Liposomal daunorubicin has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating liposomal daunorubicin, 1 is phase 3 (1 open).

Complex karyotype, Monosomy 7, and NPM1-MLF1 Fusion are the most frequent biomarker inclusion criteria for liposomal daunorubicin clinical trials.

Acute myeloid leukemia, myelodysplastic syndromes, and myeloid sarcoma are the most common diseases being investigated in liposomal daunorubicin clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Liposomal Daunorubicin
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating liposomal daunorubicin and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
DaunoXome

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.